医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Certara Partners with PUMC Hospital to Deliver PBPK Modeling and Simulation Support for Chinese Drug Development

2017年05月31日 PM09:00
このエントリーをはてなブックマークに追加


 

PRINCETON, N.J.

Certara®, the leading provider of decision support technology and consulting services for optimizing drug development and improving health outcomes, today announced that it is partnering with Phase I Unit, Peking Union Medical College (PUMC) Hospital’s Clinical Pharmacology Research Center (PUMCH-CPRC) in Beijing to help Chinese pharmaceutical companies enhance their drug development processes.

Phase I Unit at PUMCH-CPRC will employ Certara’s Simcyp® Population-based Simulator to develop physiologically-based pharmacokinetic (PBPK) models in support of Chinese new and generic drug applications to the Chinese Food and Drug Administration (CFDA).

“We are proud to support China’s efforts to foster healthcare innovation. By increasing its adoption of PBPK modeling and simulation, it will expedite its pharmaceutical companies’ drug development processes and regulatory submissions, whilst also helping to bring safer therapies to market,” said Simcyp President and Managing Director Dr. Stephen Toon.

“An increasing number of Chinese pharmaceutical companies want to use PBPK modeling and simulation as part of their drug development plans. We felt that the best way to maintain Certara’s high scientific standards for these Chinese customers and help circumvent some of the language-related commercial impediments was to partner with Phase I Unit at PUMCH-CPRC, which is one of the most prestigious academic pharmaceutical research institutions in China,” added Dr. Toon.

“We are delighted to expand our partnership with Certara and be able to provide Chinese pharmaceutical companies with modeling and simulation consulting support to strengthen their regulatory submissions,” said Professor Pei Hu, MD, professor and director of Phase I Unit at PUMCH-CPRC.

Certara and Phase I Unit at PUMCH-CPRC already have a great partnership track record. The two organizations have been working together for several years to increase PBPK modeling and simulation education and training in China and have co-hosted several national workshops.

Phase I Unit at PUMCH-CPRC uses Certara’s modeling and simulation technology for first-in-human, point-of-care, and late-phase clinical trials. It has many years’ experience using both Certara’s Simcyp Simulator and Phoenix® software and has published numerous peer-reviewed papers based on research conducted using those platforms. Phase I Unit at PUMCH-CPRC is a Phoenix Center of Excellence.

CFDA also employs Certara’s Phoenix software and is a regulatory affiliate member of the Simcyp Consortium.

PUMC Hospital, which was founded by the Rockefeller Foundation in 1921, conducts clinical research into severe, rare and complicated diseases. It has 4,000 employees and is affiliated with both PUMC and the Chinese Academy of Medical Sciences.

Certara’s Simcyp Simulator is the pharmaceutical industry’s most sophisticated platform for determining first-in-human dose selection, designing more efficient and effective clinical studies, evaluating new drug formulations, and predicting drug-drug interactions and PK outcomes in clinical populations. These include vulnerable populations such as pediatric patients, pregnant women, and patients with impaired organ function.

Phoenix is the most advanced, intuitive, and widely-used software for PK, pharmacodynamic, and toxicokinetic modeling and simulation.

Through this new partnership with PUMC Hospital, Certara is providing Chinese customers with access to its modeling and simulation technology and helping accelerate safer and more effective drug development in China.

About Certara

Certara is a leading decision support technology and consulting organization committed to optimizing drug development and improving health outcomes. Certara’s solutions, which span drug discovery through patient care, use the most scientifically-advanced modeling and simulation technologies and regulatory strategies to increase the probability of regulatory and commercial success. Its clients include hundreds of global biopharmaceutical companies, leading academic institutions, and key regulatory agencies. For more information, visit www.certara.com.

View source version on businesswire.com: http://www.businesswire.com/news/home/20170531005153/en/

CONTACT

Certara Contact:
Ellen Leinfuss, 609-216-9586
Chief
Marketing Officer
or
Media Contact:
Rana
Healthcare Solutions
Lisa Osborne, 206-992-5245
lisa@ranahealth.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • Clinigen Acquires Japan’s Largest Supplier of Unlicensed Medicines
  • Konica Minolta and Innovation Network Corporation of Japan Close Acquisition of Ambry Genetics
  • Median Technologies Appoints Vivian Wang as General Manager, China and Takashi Hayashi as Managing Director, Japan
  • Second Sight Announces Appointments of Frank Vandeputte as Vice President and General Manager, EMEA and Asia Pacific; Gregoire Cosendai as Vice President, Clinical Affairs
  • 武田薬品がALK陽性非小細胞肺がんでのALUNBRIGTM(ブリガチニブ)のピボタル第2相ALTA試験の最新データを発表